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Objective: Our institution previously reported an association between elevated C-reactive protein (CRP) and carotid artery
stenosis. Based on this finding, we sought to further evaluate the association of CRP levels with ultrasound progression
of carotid artery stenosis, and/or clinical events.
Methods: A prospective observational study of patients evaluated for carotid artery stenosis was performed at a tertiary
medical center from 2003-2007. Patients underwent serial lab draws for serum CRP, as well as serial duplex ultrasounds
of their carotid bifurcations. Examinations were performed at 6-month intervals. Initial risk factors and CRP levels were
evaluated with univariate statistics. Ultrasound progression of disease was evaluated with Kaplan-Meier curves and Cox
regression analysis.
Results: During the study period, 271 patients completed study requirements with a mean follow-up of 37 (6) months.
Initial duplex examination revealed 114 (41%) of patients had 0% to 15%, 94 (35%) had 16% to 49%, and 63 (23%) had
50% to 79% stenosis of the carotid bifurcation. Sixty-three patients (23%) demonstrated progression of disease by
ultrasound examination, 27 (10%) progressed to carotid endarterectomy, and three (1%) experienced a stroke during
follow-up. Mean CRP levels were higher among patients that progressed on duplex examination (6.7  1.28 vs 4.6  0.4
mg/dl, P < .05). Kaplan-Meier analysis revealed a significant difference in freedom from progression of carotid artery
disease for patients with 1st and 3rd quartile CRP levels (log-rank test P < .05). Adjusting for diabetes, hyperlipidemia,
hypertension, coronary artery disease, aspirin or other anti-inflammatory uses, and statin therapy, 4th quartile CRP was
independently associated with disease progression (OR 1.8, 95% CI; 1.03-2.99, P < .05).
Conclusions: High CRP levels predict ultrasound progression of disease in patients with carotid artery stenosis. In
addition, CRP levels may provide additional information to help guide ultimate therapy for evaluation and follow-up of
patients with borderline lesions identified by duplex exam. ( J Vasc Surg 2008;47:744-51.)C-reactive protein (CRP) is a nonspecific serologic
protein that is a consequence of inflammation and has
become increasingly evaluated in the context of atheroscle-
rotic coronary artery disease.1-4 C-reactive protein has been
deemed a marker of disease “activity,” and in response, the
Center for Disease Control and the American Heart Asso-
ciation has added CRP as an adjunct to traditional cardiac
risk factors for global coronary risk assessment.5 This rec-
ommendation was based on research that CRP levels inde-
pendently identify subclinical coronary disease that will
progress to coronary artery stenosis.2 Furthermore, in pa-
tients with existing coronary artery disease, CRP is predic-
tive of patients who will develop acute coronary syndromes
and of those with vulnerable plaque characteristics identi-
fied during angiography.6
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744Likewise, studies have elucidated the role of inflamma-
tion in carotid artery stenosis, unstable carotid plaques, and
ischemic strokes.7-10 Inflammatory markers, to include
CRP, correlate with intimal media thickness and are di-
rectly proportional to number of inflammatory cells in
plaque specimens. The degree of inflammation as measured
by serum biomarkers likely represents the activity of disease
and may predict patients at risk for progression of athero-
sclerosis. Because a substantial proportion of carotid artery
progression and incident ischemic strokes are largely unex-
plained by traditional risk factors, unique determinants are
needed to determine those patients at high risk.11 By
extrapolating the relationship between CRP and coronary
artery disease, it is foreseeable that CRP has the potential to
identify patients with subclinical carotid artery stenosis
most likely to progress over time. We sought to prospec-
tively evaluate the temporal relationship of CRP levels and
ultrasound progression of carotid artery stenosis, and/or
clinical events.
METHODS
This is an institutional review board-approved, pro-
spective cohort study designed to (1) evaluate the potential
relationship between CRP level and the progression of
carotid artery stenosis and (2) to compare the strength of
this relationship with traditional risk factors such as age,
hypertension, hyperlipidemia, smoking, and diabetes. The
initial phase of this protocol was to evaluate CRP levels with
baseline carotid artery stenosis, and these results have been
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protocol to further evaluate the association of CRP with
progression of disease.
Participation and enrollment into this study was made
available to all male and female patients, greater than 40
years of age, who were referred to the vascular surgery
service for possible or known unilateral, bilateral, symptom-
atic, or asymptomatic carotid artery stenosis. In addition,
patients were offered enrollment into the study as part of
the annual health-risk screening fair for military retirees
held at our institution. These patients were included in
order to ensure there was a representative cohort of patients
with minimal disease in order to follow their respective
CRP levels. Generally, patients were evaluated in an outpa-
tient setting for asymptomatic bruit, amaurosis fugax, syn-
cope, transient ischemic attacks, or recent stroke. Patients
with known disease were offered enrollment at their regu-
larly scheduled visit or during evaluation for the develop-
ment of symptoms. Patients were excluded for age less than
40 years of age, chronic infection, untreated malignant
neoplasms, or steroid use. Patients were excluded from
analysis that did not complete three follow-up visits to
include the clinical examination, carotid duplex, and labo-
ratory blood sampling. Patients who were deemed opera-
tive candidates for carotid endarterectomy on initial visit
were also excluded since they were not able to undergo
longitudinal evaluation.13
All eligible patients provided informed consent and
were enrolled by the study research nurse. A standardized
demographic and clinical history questionnaire was com-
pleted, and 6-month study visits were scheduled. Medica-
tion use was recorded by our research nurse. Patients in our
medical system receive their medications through one cen-
tral Department of Defense pharmacy. From our pharmacy,
our clinic can cross-reference medications that have been
dispensed to the patient to ensure compliance. Of the
patients taking statin therapy, 94% of the patients were
taking atorvastatin, either 20 mg or 40 mg.
All patients then underwent a vascular clinical evalua-
tion by a staff vascular surgeon. Fasting high-sensitivity
CRP and low density lipoprotein (LDL) levels were evalu-
ated at each 6-month study visit. In addition, at each study
visit, formal bilateral carotid duplex ultrasonography was
performed on all patients by a registered vascular technol-
ogist in an Intersocietal Commission for the Accreditation
of Vascular Laboratories certified vascular laboratory. The
degree of internal carotid artery stenosis was determined on
the basis of velocity criteria that has been validated yielding
stenosis classes of none (0%-15%), mild (16%-49%), mod-
erate (50%-79%), severe (80%-99%), near occlusive, and
occluded.14,15
Progression (A) of carotid artery stenosis was defined as
an increase in classification of carotid artery stenosis by
duplex ultrasound criteria. This liberal definition was uti-
lized because our initial goal was to evaluate CRP as a
potential screening tool to detect patients with early active
disease. In addition, we excluded patients with less than
three examinations. A modified analysis was performeddefining progression (B) as only those patients that devel-
oped a lesion with 50% stenosis on duplex examination,
or progression to a higher class if their baseline lesion was
50%. This second analysis was performed because a 50%
stenosis has been deemed clinically significant and has
previously determined the level of disease that is most likely
to progress over time.16,17
Individual CRP and LDL levels were calculated as
means over the study period. Because mean CRP levels
were not normally distributed secondary to outliers, they
were categorized into quartiles. Age, tobacco use in pack-
years, and mean LDL levels, highest CRP level, and CRP at
time of progression fit a normal distribution and were
analyzed as continuous variables for univariate and multi-
variate analysis. Clinical events (such as myocardial infarc-
tion, development of symptoms attributable to carotid
stenosis, stroke, and death) were determined by patient
follow-up visits and electronic medical records.
Progression of carotid artery stenosis was considered an
outcome event and modeled utilizing the Kaplan-Meier
method. Kaplan-Meier plots were carried out to the point
in time at which standard error exceeded 10% of the value
of the survival distribution (freedom from progression of
carotid artery stenosis). Curves were analyzed utilizing the
log-rank test, and significance was set at .05.
Cox regression proportional hazards modeling was uti-
lized to determine the univariate impact of traditional
atherosclerotic risk factors, baseline carotid artery stenosis,
and CRP quartiles. Variables that demonstrated P  .10
were entered into multivariate analysis. Potential con-
founders such as aspirin use, 3-hydroxy-3-methylgutaryl
coenzyme A reductase inhibitor (statin) use, and other
anti-inflammatories (nonsteroidal anti-inflammatory
drugs) were included in themultivariate model tominimize
this potential source of bias that has been shown to reduce
CRP levels. Duringmodeling, variables were removed for P
 .10, and were entered into the model if P  .05 for a
maximum of 20 iterations. Values are reported as hazard
ratios (HR) 95% confidence interval with respective P
values. Univariate and multivariate modeling were per-
formed for dichotomous endpoints, progression (A) and
progression (B). All statistical analysis was performed uti-
lizing SPSS 15.0 (2003) (Chicago, Ill).
RESULTS
Over the 3-year period of enrollment, 421 patients
were enrolled into the study and completed the initial
examination. Eighteen patients voluntarily withdrew from
the study. Of the remaining 403 patients, 271 patients
completed three or more study visits to include clinical
visits, lab draws, and carotid duplex examination; this
group comprised our study population for analysis. In
regards to the patients that did not meet inclusion criteria,
109 (83%) were patients who were enrolled during our
annual health screening fair. The remainder was excluded
secondary to inadequate follow-up for analysis. Evaluating
the demographics of the population not captured in this
study, the average age was 66 (7) years, 67% reported a
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and 68% hypertensive. Twenty-eight percent reported cor-
onary artery disease, 6% transient ischemic attacks, and 3%
infrainguinal occlusive disease. Eighty-six percent of pa-
tients not captured for longitudinal evaluation had initial
carotid stenosis (CS) of 0% to 49%.
The baseline demographics and clinical risk factors for
the cohort studied are listed in Table I. The population was
predominately over the age of 60 years, and the majority of
patients had a history of smoking, hypertension, and hyper-
lipidemia. Diabetes and coronary artery disease were iden-
tified in 27% and 35%, respectively. Forty-two percent of
patients had no carotid artery stenosis at the beginning of
the study; the remainder had either mild or moderate
disease. There were no patients in the severe category. The
mean follow-up period was 37 (6) months, and the
median number of follow-up visits per patient was six
(interquartile range: 5-7). Sixty-three patients (23%) met
criteria for progression (A), whereas 46 (17%) met criteria
for progression (B).
Because cohort mean CRP levels did not fit a normal
distribution, we first evaluated mean levels by making a
parametric transformation. Excluding values 3 standard
deviations from the mean, mean SD CRP levels were
significantly higher among patients that progressed com-
pared to those with stable carotid artery stenosis (6.7 
1.28 vs 4.6  0.4 mg/dl, P  .05). In order to include
patients with high mean CRP levels, we analyzed individual
mean CRP as a categorical variable stratified into the fol-
Table I. Cohort demographic features, clinical risk
factors, and baseline carotid artery stenosis
n  271 patients
Mean age (y) 70 (8)
Male sex 134 (49%)
Race, nonwhite 26 (10%)
Risk factors:
Current smoking 26 (10%)
Any smoking history 191 (68%)
Hyperlipidemia 181 (67%)
Diabetes 74 (27%)
Hypertension 199 (74%)
Coronary artery disease 95 (35%)
Stroke or transient ischemic
attacks
67 (25%)
Infrainguinal occlusive
disease
49 (18%)
Medications:
Statin therapy 158 (58%)
Aspirin use 190 (70%)
Other anti-inflammatory
medication
61 (23%)
Baseline classification internal
carotid artery stenosis
None (0%-15%) 114 (42%)
Mild (15%-49%) 94 (35%)
Moderate (50%-79%) 63 (23%)
Severe (80%-99%) —
Preocclusive or occluded —lowing quartiles: 1st quartile (0.26-1.59 mg/dl), 2nd quar-tile (1.60-3.17 mg/dl), 3rd quartile (3.19-6.04 mg/dl),
and 4th quartile (6.12-22.07 mg/dl). Utilizing Kaplan-
Meier analysis, CRP quartiles were compared for progres-
sion A and for progression B. For both endpoints, there was
no significant difference between quartiles 1to 3; however,
there was a significant freedom from progression for both
(A) and (B), Figs 1 and 2, respectively. For the remainder of
the analysis, individual mean CRP levels were grouped as
1st to 3rd quartiles and 4th quartile.
Our analytic strategy was to use univariate hazards
modeling to identify variables within our cohort associated
with progression of carotid artery stenosis (Table II). Of
the traditional risk factors subjected to unadjusted analysis
for progression (A), only history of hypertension (hazard
ratio (HR), 2.22; 95% confidence interval (CI), 1.12-4.63;
P  .05) and history of coronary artery disease (HR, 1.82;
Fig 1. Kaplan-Meier method curves show probability of freedom
from progression (A) as a function of time. Curves are the result of
stratification of mean Hs-CRP levels into two groups: 1st-3rd
quartiles and 4th quartile. Numbers below the figure denote the
number of at risk patients for each subgroup. Progression (A) of
carotid artery stenosis was defined as an increase in classification of
carotid artery stenosis by duplex ultrasound criteria.
Fig 2. Kaplan-Meier method curves show probability of freedom
from progression (B) as a function of time. Curves are the result of
stratification of mean Hs-CRP levels into two groups: 1st-3rd
quartiles and 4th quartile. Numbers below the figure denote the
number of at risk patients for each subgroup. Progression (B)
defined as only those patients that developed a carotid lesion with
50% stenosis on duplex examination, or progression to a higher
class if their baseline lesion was 50%.95% CI, 1.11-2.98; P  .05) reached statistical signifi-
22.07
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for inclusion in the multivariate model. Degree of baseline
carotid artery stenosis did not correlate with progression
and was not significant. Fourth quartile CRP (HR, 1.54;
95% CI, 1.06-2.60; P  .05) was significantly associated
with progression (A).
Because very little is known about population normal
values for CRP levels, CRP was analyzed in multiple varia-
tions. Since patients had a median of six values, we were
able to evaluate several temporal aspects of CRP that were
not significant on univariate analysis (statistical values not
presented in Table II). The absolute CRP level drawn at the
time of progression was not associated with progression of
disease by duplex examination. The percentage of CRP
increase, peak CRP level during follow-up, and CRP vari-
ance were not associated with progression of disease.
In themultivariate Cox regression analysis adjusting for
hypertension, coronary artery disease, diabetes, hyperlipid-
emia, aspirin or other anti-inflammatory agent, and statin
Table II. Cox regression analysis utilizing a univariate mo
Variables
Endpoint of progression (A)a
Univariate model Multivariat
HRc P HRc
Age (y)d 1.01 (0.98-1.04) .26
Sex
Female 1.0e
Male 1355 (0-105) .89
Race
White 1.0e
Non-white 1543 (0-108) .92
Smoking 1.44 (0.81-2.55) .20
Tobacco (pck-y)d 1.0 (0.99-1.02) .18
Diabetes 1.58 (.94-2.66) .08 1.24 (0.73-2.1
HLP 1.69 (0.95-3.01) .08 0.99 (0.98-1.0
LDL (mg/dL)d 0.99 (0.98-1.00) .17
HTN 2.22 (1.12-4.63) .05 2.0 (0.98-4.1
CAD 1.82 (1.11-2.98) .05 1.53 (0.93-2.5
PVD 1.32 (0.72-2.40) .35
Stroke or TIAs 1.41 (0.68-2.93) .36
Baseline CS
0% 1.0e
1%-15% 103 (0-106) .90
16%-49% 104 (0-107) .91
50%-79% 103 (0-106) .90
CRP quartilesf
1st-3rd 1.0e 1.0e
4th 1.54 (1.06-2.60) .05 1.8 (1.03-2.9
CS, Carotid stenosis; HR, hazard ratio; HLP, hyperlipidemia; LDL, low
peripheral vascular disease (infrainguinal occlusive disease); TIA, transient i
aThe first analysis was performed with the primary endpoint being a progr
repeated with the endpoint being progression to CS of greater than 50% (p
stenosis was 50% .
bVariables with P  .10 by univariate analysis were included in the mu
anti-inflammatory agent, and statin use.
cHazard ratios include the 95% confidence interval in brackets. Bolded haza
dVariables were analyzed as continuous variables; therefore, hazard ratios fo
value of the variable. All remaining variables were analyzed as categorical va
eRepresents the reference category for the given variable.
fCRP values for 1st-3rd quartile (0.26-6.04 mg/dL) and 4th quartile (6.12-use, 4th quartile mean CRP level was independently associ-ated with progression (A) (HR, 1.8; 95% CI, 1.03-2.99; P
 .05). For progression (A), hypertension and coronary
artery disease approached statistical significance, but none
of the traditional risk factors imparted independent predic-
tive value to explain the variance of progression (A).
In addition to evaluating the impact of statin therapy,
we further evaluated the impact of inadequate statin ther-
apy (defined as a mean LDL level of 100 mg/dl and on
statin therapy) and the impact of potentially high-risk pa-
tients who were not appropriately on statin therapy (de-
fined as a individual mean LDL level of 100 mg/dl and
not taking a statin medication). The mean LDL for the
entire cohort was 98 (28) mg/dl. Evaluating those pa-
tients taking statin therapy, 111(71%) hadmean LDL levels
100 mg/dl (effective statin therapy), and 46 (29%) had
mean LDL levels 100 mg/dl (ineffective statin therapy).
Ineffective statin therapy was tested as a potential covariate
for Progression A (HR  1.40, 95% CI; 0.77-2.52, P 
.263) and was not significantly associated. In addition,
ollowed by multivariate modeling.
Endpoint of progression (B)a
elb Univariate model Multivariate modelb
P HRc P HRc P
1.03 (0.49-1.1) .06 1.03 (0.99-1.07) .06
1.0e
1435 (0-106) .92
1.0e
1112 (0-107) .95
1.51 (0.89-2.52) .21
1.0 (.99-1.02) .20
.42 1.9 (1.08-3.53) .05 1.9 (1.03-3.47) .05
.38 2.47 (1.15-5.29) .05 1.92 (0.87-4.23) .10
0.99 (0.98-1.00) .18
.06 3.13 (1.23-7.93) .05 2.62 (1.03-6.68) .05
.09 1.95 (1.09-3.49) .05 1.45 (0.8-2.64) .22
1.31 (0.65-2.62) .45
1.48 (0.85-3.24) .27
1.0e
102 (0-1012) .91
103 (0-1014) .89
103 (0-1014) .88
1.0e 1.0e
.05 1.61 (1.01-2.95) .05 1.44 (0.87-2.66) .23
ty lipoprotein; HTN, hypertension; CAD, coronary artery disease; PVD,
ic attacks; Hs-CRP, high sensitivity C-reactive protein.
in CS to the next class of disease, progression (A). The analysis was then
stolic velocity  125 cm/sec) or as an increase to the next class if baseline
iate model as well as potential confounding covariates: aspirin or other
ios represent values that reached P  .05.
variables represent the increased risk associated with 1 unit increase in the
s.
mg/dL).del f
e mod
2)
)
2)
1)
9)
-densi
schem
ession
eak-sy
ltivar
rd rat
r these
riablethere were 65 (60%) patients not taking a statin that had
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risk cohort of patients was also tested as a potential covari-
ate for Progression A (HR  0.89, 95% CI; 0.64 to 1.80,
P .05) but was not significant.
A modified analysis was performed changing the di-
chotomous endpoint to progression (B) and repeating
both the univariate and multivariate analysis (Table II). In
the unadjusted analysis, diabetes (HR, 1.9; 95% CI, 1.08-
3.53; P  .05), hyperlipidemia (HR, 2.47; 95% CI, 1.15-
5.29; P  .05), hypertension (HR, 3.13; 95% CI, 1.23-
7.93; P .05), coronary artery disease (HR, 1.95; 95% CI,
1.09-3.49; P .05), and 4th quartile CRP (HR, 1.61; 95%
CI, 1.01-2.95; P  .05) were all associated with progres-
sion (B). Paralleling the results of univariate analysis for
progression (A), degree of baseline carotid artery stenosis
was not associated with progression (B).
Performing the multivariate analysis adjusting for age,
diabetes, hyperlipidemia, hypertension, coronary artery dis-
ease, aspirin or other anti-inflammatory agent, and statin
use, 4th quartile CRP level was not independently predic-
tive of progression (B). Traditional risk factors accounted
for all the variance in progression B. History of diabetes
(HR, 1.9; 95% CI, 1.03-3.47; P  .05) and hypertension
(HR, 2.62; 95% CI, 1.03-6.68; P  .05) were indepen-
dently predictive of progression (B); age and coronary
artery disease approached statistical significance.
In order to evaluate for unmeasured covariates that
could potentially confound our results, we repeated the
analysis with a 75% and 50% random sample of our cohort;
the results of the univariate and multivariate analysis were
unchanged. Although baseline carotid artery stenosis clas-
sification was not associated with progression in either
analysis, we also repeated the analysis stratifying patients by
those with baseline disease (defined as CS50%) and those
without disease (defined as CS50%). Presence of baseline
disease did not have a significant impact on disease progres-
sion in either analysis progression (A) or (B).
During the follow-up period, 27 (10%) carotid endar-
terectomies were performed, 2 (1%) developed symptoms
attributable to CS, 3 (1%) experienced ischemic strokes, 18
(9%) experienced myocardial infarctions, and 10 (5%)
deaths (all cause mortality) occurred. In regard to the two
patients that developed symptoms, both patients pro-
gressed from 15% to 49% CS to a lesion greater than 70%,
and one of the patients had a CRP level in the 4th quartile.
Of the patients that progressed to carotid endarterectomy,
25 (93%) were patients with asymptomatic disease that
progressed to lesion of 80%. Eleven (41%) had a baseline CS
of 15% to 49%with only two patients exhibiting 4th quartile
CRP levels, and 16 (59%) began with a baseline CS of 50%
to 79% with 6 (38%) exhibiting 4th quartile CRP levels.
Because there were very few clinical events in this popula-
tion, a composite endpoint (including stroke, myocardial
infarction, and death) was evaluated, and there was no
association of individual mean CRP level quartiles with
these combined events (Fig 3). Analyzing the impact of 4thquartile mean CRP on this composite outcome (HR, 0.46;95% CI, 0.16-1.35; P  .16), there was not a significant
association.
DISCUSSION
The first objective of this study was to examine the
prospective relationship of CRP and progression in classifi-
cation of carotid artery stenosis documented by duplex
examination. To this endpoint, we found that there was no
association with CRP at the time of duplex progression,
percentage CRP increase, peak CRP value, or variance in
CRP over the study period. Only 4th quartile mean CRP
levels (6.12-22.07 mg/dl) were significantly associated
with carotid artery stenosis progression, irrespective of def-
inition, progression (A) or (B).
Our second objective was to evaluate the strength of
this relationship compared with traditional risk factors for
carotid disease and degree of baseline carotid artery steno-
sis. In regard to progression (A), 4th quartile means CRP
exhibited a clear impact on progression with a HR of 1.8,
andmost notably, CRPwas the only significant factor in the
multivariate analysis. While traditional risk factors had HRs
of similar magnitude, they did not reach statistical signifi-
cance; only hypertension and coronary artery disease ap-
proached statistical significance in this cohort. In the eval-
uation of progression (B), 4th quartile was again associated
with progression in the univariate analysis, but utilizing this
modified definition for progression to clinical disease
50%, more traditional risk factors (hypertension, coro-
nary artery disease, diabetes, hyperlipidemia) were also
significantly associated with progression. The independent
association of 4th quartile CRP was no longer apparent
when adjusting for traditional risk factors; only two covari-
ates, diabetes (HR  1.9) and hypertension (HR  2.6),
were independently predictive of progression (B).
In this prospective cohort of patients followed over the
course of 37(6) months, persistently elevated individual
mean CRP levels (4th quartile mean CRP levels) had a
Fig 3. Kaplan-Meier method curves show probability of freedom
from composite endpoint (myocardial infarction, stroke, and
death) as a function of time. Four curves are the result of stratifi-
cation of mean Hs-CRP levels into quartiles. Numbers below the
figure denote the number of at risk patients for each subgroup.compelling association with carotid artery stenosis progres-
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duplex progression, highest CRP value recorded, change in
CRP, and CRP variance were not predictive; however,
persistently elevated mean CRP values where associated
with progression. This suggests that there is a chronic
systemic inflammatory process associated with progression,
and acute fluctuations in CRP have little value in predicting
progression of disease.
The independent impact of this progression was pro-
found for our initial outcome measure, progression (A),
and CRP was more predictive than traditional risk factors
(hypertension, diabetes, hyperlipidemia, coronary artery
disease, and smoking) that have been established for carotid
disease progression. The chosen definition of progression
(A) was utilized to detect patients with mild to moderate
disease who were at risk for progression. This outcome
would be suitable for screening programs and would po-
tentially detect vulnerable patients at an early stage, which
would then have implications for early medical manage-
ment.
Our results reinforce published research linking CRP
levels to carotid artery disease. CRP levels have been asso-
ciated with baseline carotid artery stenosis and to be asso-
ciated with varying plaque morphologic features.18 The
degree of inflammatory cells (T lymphocytes, activated T
lymphocytes, andmacrophages) within plaque specimens is
proportional to CRP levels;10 therefore, a systemic marker,
CRP, is a plausible surrogate for local plaque activity.
Studies have addressed the utility of CRP in patients
with asymptomatic carotid artery stenosis but with varying
populations and contrasting results.19,20 In a large popula-
tion based trial, Sander et al found CRP to directly correlate
with progression in intima-media thickness (IMT) but also
found age, hemoglobin A1c, LDL level, hypertension, and
body-mass index to predict progression defined as an in-
crease in IMT.19 These differences were due to the larger
population cohort and increased power to determine small
statistical differences. In addition, the definition of progres-
sion was significantly different than that used in this study;
they defined progression as an increase in IMT. Despite
these differences, the magnitude of the HR for 4th quartile
CRP (HR, 1.97; 95% CI, 1.44-3.0; P  .05) for nondia-
betic patients was not clinically different than that found in
this study (HR, 1.8; 95% CI, 1.03-2.99; P  .05).
Schillinger et al20 followed 1268 patients over a median
follow-up of 7.5 months and found CRP at baseline and at
time of follow-up to independently correlate with progression
as defined as the increase of duplex criteria by at least one
category (analogous to progression (A) in this study). They
found age, smokinghistory, baseline degree of stenosis70%,
and CRP 4th and 5th quintiles to be independently associated
with progression. Again, their cohort was much larger than in
this study, and the population had approximately 10% of
patients with baseline stenosis70%, whereas our cohort had
no patient with this level at disease at baseline. In addition,
they found smoking to impact progression. Despite evaluat-
ing any smoking history and the number of pack-years, we
were unable to confirm this relationship. Similar to our study,the highest CRP levels at baseline and at follow-up predict
those patients likely to progress; this reinforces our conclusion
that persistently elevated CRP levels are related to carotid
stenosis progression.
There are several limitations that deserve mention. The
patient population is comprised of both vascular surgery refer-
rals and patients enrolled as part of a health fair screening
process. Although we were unable to demonstrate any differ-
ences based on baseline carotid artery stenosis, there may be
innate unmeasured differences in these two patient groups
that could not be determined from this study. While the
number of patients was adequate to statistically detect a dif-
ference in CRP levels for progression of disease, the potential
for a type I and type II error exists. Traditional cardiac risk
factors that reached univariate significance for progression (A)
may have achieved statistical significance in the multivariate
model with a larger sample size. Also in this regard, 4th
quartile CRP may have achieved statistical significance in the
multivariate model for progression (B). The definitions of
carotid artery progression rely on the ultrasound determina-
tion of carotid artery stenosis. There is a large amount of
unmeasured variance in the interpretation of the duplex ex-
amination, the ultrasound equipment, local laboratory crite-
ria, and the given examiner. We attempted to minimize this
error by excluding patients that did not have more than three
examinations, and all examinations were performed by two
ultrasound technicians. However, in the absence of more
precise imaging, some of these patients may have had carotid
plaques too small to be detectable by duplex ultrasound; this
represents uncontrolled variability.
In the present study, the results suggest the potential
for future management strategies. The impetus of the study
was to identify patients with asymptomatic disease that may
be vulnerable to rapid progression, and thus, guide either
follow-up strategies or medical management strategies.
Duplex-imaging has been the gold standard for screening
patients and following progression of disease in the vascular
laboratory. Patients with persistently elevated mean CRP
levels progress at a more rapid rate and could potentially
benefit from a closer follow-up interval. Another area of
developing research is the utility of magnetic resonance
imaging (MRI) in determining carotid plaque morphol-
ogy, and determining risk associated with morphologic
changes.21 Zhao et al has demonstrated the modification of
carotid plaque morphology measured by MRI utilizing
lipid lowering agents.22 Future analyses would be needed
to determine if CRP was an appropriate screening test to
identify patients with asymptomatic carotid lesions that
could benefit from MRI imaging and directed therapy.
Anti-inflammatory therapies have already beendevised for
coronary artery disease, and these agents are primarily aspirin
and statin medications.23 Both agents have been identified as
having a lowering effect onCRP and their impact extends to a
reduction in stroke rates.24,25 The benefits are irrespective of
the lipid-lowering effect and the antiplatelet impact of these
agents. Blake et al has devised CRP screening regimens for
patients without hyperlipidemia and treating patients with
targeted statin therapy to an endpoint of CRP reduction and
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same benefits would be applicable to patients with asymptom-
atic carotid artery disease that have persistently elevated CRP
levels. However, the benefits of pharmacologic CRP modifi-
cation would need to be demonstrated in a prospective anal-
ysis to demonstrate an impact on carotid artery progression
and clinical event rates.
CONCLUSION
This study confirms that there is a temporal relationship
with persistently elevated C-reactive protein levels and the
propensity for progression of carotid artery stenosis. The
consequence of 4th quartile mean CRP levels over time has an
independent impact on carotid artery progression greater than
the impact of traditional demographic and clinical risk factors
in this cohort of patients with subclinical disease. In addition,
the impact of CRP was independent of baseline carotid artery
stenosis. These results suggest that serologic CRP levels are a
marker for progression of disease and may have utility for the
management of carotid artery disease and global carotid risk
assessment. This may provide additional diagnostic value for
evaluation and follow-up of patients with subclinical carotid
artery stenosis identified by duplex examination.
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Dr Pevec (Sacramento, Calif). Captain Arthurs and colleagues
have presented a prospective observational study evaluating the
association of C-reactive protein with the progression of carotid
stenosis. This study, including 271 patients over 3 years, provides
valuable information on the association of CRP and inflammatory
markers and the progression of atherosclerosis. The authors are to
be commended for conducting this longitudinal study. The au-
thors suggest that elevated CRP levels predict progression of
carotid artery stenosis and that the measurement of CRP in pa-
tients with carotid artery stenosis may be of some clinical benefit.
I have several questions. Patients with CRP in the highest
quartile were found to be at higher risk for progression of carotid
artery stenosis. The CRP quartiles were assigned retrospectively by
taking the average of the CRP measurements obtained from each
study patient every 6 months. While this is useful in helping to
understand the relationship of CRP with progression of carotid
stenosis in general, looking retrospectively at an average of values
measured over several years, there is not a benefit in predicting
future progression of stenosis in an individual patient. Is there a
single cutoff value of CRP that can be used to predict progression
of carotid stenosis? Can the authors provide positive- and negative-
predictive values for some level of CRP, for instance, greater than
6 mg/dL, which was their level in the fourth quartile?
The authors defined progression of carotid stenosis in two
ways. Type A included progression from any category of stenosis to
a higher category of stenosis. Type B included only stenosis that
progressed to 50% or greater or from 50% to 79% to a greater
stenosis. The authors do not state how they define the categories of
stenosis, but as the authors are from Washington, one can assume
they use the Strandness criteria. If this is true, progression from 0%
to 15% to 16% to 49% stenosis is based upon subjective criteria—
plaque appearance and presence of spectral broadening—while
progression to a greater than 50% stenosis is based on objective
velocity criteria. While type B progression based on objective
duplex velocity measurements correlated with elevated CRP levels
on univariate analysis, this correlation was not significant on mul-
tivariate analysis. Only when progression based upon subjective
duplex assessment was included, so-called type A progression, were
elevated CRP levels predictive on multivariate analysis. A full 41%
of study patients had 0% to 15% carotid stenosis at entry. Lack of
independent correlation of elevated CRP with objective progres-
sion of carotid stenosis seems to greatly weaken the importance of
these findings. Can the authors comment on this please?
Finally, is the measurement of CRP of clinical benefit in the
management of patients with carotid stenosis? In the paper the
authors suggest that decreasing inflammation with aspirin and/or
statins may be of benefit in patients with carotid stenosis and
elevated CRP. Shouldn’t all patients with carotid stenosis be on
aspirin and a statin drug?I would like to compliment the authors on a well-performed
and well-presented study that increases our understanding of the
influence of inflammation on progression of atherosclerosis. I
would like to thank the authors for providing me with a copy of
their manuscript in advance of the meeting, and I would like to
thank the program committee for the privilege of discussing this
paper. Thank you.
Dr Arthurs. I would like to thank Dr Pevec for his insightful
comments. I will start with his second question first as it addresses
the matter of our design of the study and the difficulty in doing so
from the onset. It comes down to the subjective nature of mild vs
moderate disease on duplex and whether that plays a part in the
study. It absolutely does. It is extremely subjective, and we at-
tempted to control for that variability. That is why we excluded all
patients with less than three examinations, so the patient either had
two normal examinations with one abnormal examination on the
third study, or the patient had a normal study with two subsequent
examinations read out as moderate by the same two vascular
technicians. In addition, during this time, the same two vascular
staff surgeons read the examinations. Because our ultimate goal
with this study was observational evaluation of progression of
patients with subclinical disease, we felt that more sensitive imag-
ing modalities would not justify the cost of performing examina-
tions at 6-month intervals.
His second question—ultimately is there a cutoff value for
CRP? I think if we look at where the coronary literature has utilized
CRP, the CRP values that are abnormal are not far from the
definitions utilized for abnormal CRP. In our study, 6 is the cutoff,
but ultimately, that just applies to this cohort. I think the message
is that we were not trying to identify patients that had high-grade
stenosis. We were looking at that population of patients that either
came with no stenosis or had aminimal stenosis withminimal to no
risk factors. From our study, CRP may be most applicable in those
patients without any risk factors and minimal carotid disease who
have a CRP level above 6. They appear to be at higher risk for
progression of disease based on our findings. We are trying to
quantify the idea that there is inflammation as a marker of overall
disease risk or patient vulnerability.
That rolls into the third question of shouldn’t all patients who
have carotid artery stenosis be on a statin or aspirin. Absolutely.
However, a patient has no risk factors, no lesion on examination,
but comes into our office and has a CRP level that is persistently
elevated, whether it be 4 mg/dL or 6 mg/dL, should there be
different goals in medical treatment for that patient? We can’t
answer that question with this study, but based on our study, those
patients are at a higher risk of carotid stenosis progression. Finally,
if a patient has a normal LDL and an elevated CRP, should you
treat that patient with a statin or some other anti-inflammatory
modality? Thank you.
